Clinical trial
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
NCT03419975
Study timeline
Study start (actual)2016-04-26Date precision: day
Registry last updated2019-09-04
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Primary Open-angle Glaucomaunresolved
Ocular Hypertensionunresolved
Interventions
TJO-002DRUG
LatanoprostDRUG · verified · RxNorm: latanoprost
Sponsors & collaborators
Taejoon Pharmaceutical Co., Ltd.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03419975 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.